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Abstract
Introduction Extracorporeal circulation induces hemostatic
alterations that lead to inflammatory response (IR) and
postoperative bleeding. Tranexamic acid (TA) reduces
fibrinolysis and blood loss after cardiopulmonary bypass (CPB).
However, its effects on IR and vasoplegic shock (VS) are not
well known and elucidating these effects was the main objective
of this study.
Methods A case control study was carried out to determine
factors associated with IR after CPB. Patients undergoing
elective CPB surgery were randomly assigned to receive 2 g of
TA or placebo (0.9% saline) before and after intervention. We
performed an intention-to-treat analysis, comparing the
incidence of IR and VS. We also analyzed several biological
parameters related to inflammation, coagulation, and fibrinolysis
systems. We used SPSS version 12.2 for statistical purposes.
Results In the case control study, 165 patients were studied,
20.6% fulfilled IR criteria, and the use of TA proved to be an
independent protective variable (odds ratio 0.38, 95%
confidence interval 0.18 to 0.81; P < 0.01). The clinical trial was
interrupted. Fifty patients were randomly assigned to receive TA
(24) or placebo (26). Incidence of IR was 17% in the TA group
versus 42% in the placebo group (P = 0.047). In the TA group,
we observed a significant reduction in the incidence of VS (P =
0.003), the use of norepinephrine (P = 0.029), and time on
mechanical ventilation (P = 0.018). These patients showed
significantly lower D-dimer, plasminogen activator inhibitor 1,
and creatine-kinase levels and a trend toward lower levels of
soluble tumor necrosis factor receptor and interleukin-6 within
the first 24 hours after CPB.
Conclusion The use of TA attenuates the development of IR and
VS after CPB.
Trial registration number ISRCTN05718824.
Introduction
Cardiopulmonary bypass (CPB) may activate an inflammatory
response (IR) involving contact system, complement, cytokine,
and coagulation-fibrinolytic cascades, among others. The
coagulation-fibrinolytic cascades and the IR, though in many
respects separate processes, are closely interconnected [1].
Several preoperative and perioperative risk factors for IR have
CI = confidence interval; CPB = cardiopulmonary bypass; ICU = intensive care unit; IL-6 = interleukin-6; IR = inflammatory response; OR = odds 
ratio; PAI-1 = plasminogen activator inhibitor 1; PT = prothrombin time; STNFR = soluble tumor necrosis factor receptor; TA = tranexamic acid; VS 
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been proposed [2,3]. The incidence of vasoplegic shock (VS),
the most severe presentation of IR, may be as high as 10% [4].
Numerous strategies to reduce IR and bleeding in high-risk
patients exist, among which is the use of aprotinin [5]. Like
aprotinin, tranexamic acid (TA) inhibits fibrinolysis (that is, plas-
min activity and D-dimer formation), but its effect on IR remains
unclear. Additionally, there is evidence that fibrinolysis is a
marker for the onset of systemic inflammation. [6].
This paper describes a study in two parts. First, we performed
a case control study to determine risk factors associated with
IR in patients who underwent CPB. Second, we carried out a
randomized, double-blind, placebo-controlled study to test the
hypothesis that inhibition of excessive fibrinolysis by TA could
reduce the incidence of IR and VS after CPB. The second
study was interrupted because of the high incidence of
adverse effects observed in the placebo group. Thus, we
present data of an interim analysis.
Materials and methods
The study was approved by the institutional ethics committee
of the University Hospital of the Canary Islands (La Laguna,
Spain) and was conducted according to the Declaration of
Helsinki. The study consisted of two parts.
Part 1: Assessment of postoperative incidence and 
protective/risk factors for inflammatory response after 
cardiopulmonary bypass
After obtaining informed written consent, we prospectively
enrolled 191 consecutive Caucasian adult patients scheduled
for cardiac surgery with CPB between January 2002 and Feb-
ruary 2003. To avoid the effect of confounding factors on the
IR, patients with endocarditis and those admitted with cardio-
genic shock or with intra-aortic counterpulsation balloon were
excluded (n  = 26). Finally, a total of 165 patients were
included. No patients received perioperative anti-inflammatory
agents such as corticosteroids or nonsteroidal anti-inflamma-
tory drugs.
IR was clinically defined as a core body temperature of greater
than 38°C (100.4°F) in the first 4 hours after intervention, a
systemic vascular resistance index of less than 1,600 dyn-sec-
onds/cm5 per square meter, and a cardiac index of greater
than 3.5 L/minute per square meter. VS was defined as per-
sistent hypotension (mean arterial pressure of less than 70 mm
Hg) requiring norepinephrine for at least 4 hours after failure to
respond to appropriate volume expansion (pulmonary capillary
wedge pressure of greater than 15 mm Hg). Serum concen-
trations of interleukin-6 (IL-6) were measured at 4 hours after
CPB (Materials and methods, part 2). Risk factors associated
with IR after CPB, including demographic variables, comorbid
conditions, preoperative medication, duration of CPB, aortic
crossclamp time, and the use of antifibrinolytic drugs, were
investigated. Perioperative management of the groups was
similar in the two studies (Materials and methods, part 2),
except for the study medication. In this study, the surgeon
decided when to use TA.
Part 2: Prospective double-blind trial of tranexamic acid 
effect on inflammatory response after cardiopulmonary 
bypass
We performed a randomized, double-blind, placebo-control-
led study with consecutive Caucasian adult patients undergo-
ing elective CPB surgery from February to May 2004.
Postoperative care of the patients was performed in a 24-bed
intensive care unit (ICU) at a university hospital. We excluded
emergency interventions, patients with a history of chronic
coagulopathy (prothrombin time [PT] of less than 50% or inter-
national normalized ratio of greater than 2 and platelets of less
than 50,000/mm3 or aggregation dysfunction), renal failure
(creatinine of greater than 2 mg/dL), chronic hepatopathy
(Child B or higher degree), use of immunosuppressant drugs,
endocarditis, sepsis in the first 24 hours after intervention, or
unwillingness to enroll. Before CPB, participants had normal
bleeding time, platelet collagen/epinephrine and collagen/
ADP closure time, PT, activated partial thromboplastin time,
and thrombin time. None of the patients received anti-inflam-
matory agents such as corticosteroids or nonsteroidal anti-
inflammatory agents, including acetyl salicylate acid or clopi-
dogrel or immunosuppressants, on the previous 5 days and
the first 24 hours following intervention.
After informed written consent was obtained, patients were
randomly assigned by independent pharmacists using a list of
pseudorandomized numbers to receive coded infusions of
either TA or placebo (0.9% saline) with doses of 2 g pre-CPB
and post-CPB after protamine administration (using the same
protocol as in the previous part of the study). The code was
revealed once recruitment, data collection, and laboratory
analyses were completed. The primary endpoint was to test
the effect of TA on the incidence of IR and VS in patients
undergoing elective CPB. Secondary endpoints were biologi-
cal parameters related to inflammation, coagulation, and fibri-
nolysis systems.
Data collection
Demographic variables, comorbid conditions, perioperative
clinical data, and postoperative outcomes (IR, VS, duration of
mechanical ventilation, postsurgical ICU stay and hospital
stay, and mortality) were recorded. Core body temperature,
biochemical determinations (hematology, inflammation, coag-
ulation, and fibrinolysis), and hemodynamic parameters were
recorded before intervention (baseline), on admission to the
ICU after surgery (0 hours), and at 4 hours and 24 hours after
intervention. In addition, blood loss measured by tube chest
drainage and the amount of hemoderivatives used, as well as
its frequency, were collected after intervention at the above
time points and when chest tubes were removed (defined asAvailable online http://ccforum.com/content/11/6/R117
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total bleeding). Surgical risk was calculated by Parsonnet
score.
Anesthetic procedures were standardized and consisted of an
opioid-based anesthetic supplemented with volatile anes-
thetic and muscle relaxants. All interventions were performed
by the same surgical team with wide experience in these sur-
gical interventions. All patients were preoperatively monitored
with a pulmonary artery continuous thermodilution catheter
(Edwards Lifesciences LLC, Irvine, CA, USA). Neither heparin-
coated circuits nor leukocyte filters were used. The extracor-
poreal circuit consisted of a hardshell membrane oxygenator
(Optima XP; Cobe, Denver, CO, USA, or Quantum Lifestream
International, Inc., Woodlands, TX, USA), a Tygon™ (Dideco
s.r.l., Mirandola, Italy) extracorporeal circuit, and a Medtronic™
Biopump (Medtronic, Inc., Minneapolis, MN, USA) centrifugal
pump. Below hypothermic temperatures of 28°C to 30°C, the
pump flow was adjusted to maintain a mean arterial pressure
of greater than 60 mm Hg and a flow index of 2.2 L/minute per
square meter. Myocardial protection was achieved using ante-
grade, cold, St. Thomas 4:1 sanguineous cardioplegia. The
circuit was primed with 30 mg of heparin followed by an initial
dose of 3 mg/kg and further doses when necessary to achieve
and maintain an activated clotting time of 480 seconds. To
reverse the effect of heparin, protamine was used based on
blood heparin levels measured by Hepcon® (Medtronic, Inc.).
A blood salvage device was used in all patients. The transfu-
sion trigger was a hemoglobin threshold of less than 8 g/dL,
PT of less than 50%, and platelets of less than 50,000/mm3.
Fluid management was carried out to achieve 8 to 12 mm Hg
of central venous pressure or 12 to 15 mm Hg of pulmonary
artery occlusion pressure at zero positive end-expiratory pres-
sure by infusions of crystalloids and colloids. Catecholamine
support, when necessary, was used as follows: Norepine-
phrine was titrated to achieve a mean arterial pressure of
greater or equal to 70 mm Hg, and dobutamine was titrated to
achieve a cardiac index of greater or equal to2.5 L/minute per
square meter. Amines were tapered off in steps of 0.02 and 1
μg/kg per minute, respectively.
Cytokine levels
Soluble tumor necrosis factor receptor (STNFR)-1 and IL-6
(normal range: less than 5.9 pg/mL; intra-assay variation:
4.5%) were measured using an automatic immunoenzyme
assay system (IMMULITE ONE™; Diagnostic Products Corpo-
ration, now part of Siemens AG, Munich, Germany). STNFR-1
EASIA (normal range: 3.4 to 10.8 ng/mL; intra-assay variation:
1.7%) are solid phase enzyme-amplified sensitivity immu-
noassays performed on a microtiter plate (, Biosource Tech-
nologies, Inc., Fleunes, Belgium).
Coagulation and fibrinolysis determination
Quantitative plasminogen activator inhibitor 1 (PAI-1) antigen
(normal range: 2 to 47 ng/mL; intra-assay variation: 3.7%) and
tissue plasminogen activator antigen levels (normal range: less
than 9.0 ng/mL; intra-assay variation: 4.2%) were measured
using an enzyme-linked immunosorbent assay (IMUBIND®;
American Diagnostica Inc., Stamford, CT, USA). D-dimer (nor-
mal range: less than 300 ng/mL; intra-assay variation: 3%)
was measured using an immunoturbidimetric test (D-dimer
PLUS; Dade Behring, now part of Siemens AG).
Statistical analysis
Comparisons between groups (patients with and without IR or
the TA group versus placebo group) were performed using the
Pearson χ2 test or Fisher exact test for categorical variables
and the Student t test or the Mann-Whitney U test for contin-
uous variables, as appropriate. Logistic regression analysis
(forward stepwise conditional) was used to identify independ-
ent risk factors associated with IR. Initially, only variables with
a P value of less than 0.15 (TA, clamping time, and mixed car-
diac surgery) in the univariate analysis were incorporated. To
perform the controlled study, a sample size of 100 patients
was required to detect a statistically significant reduction of at
least 20% in IR by TA. Assuming an incidence of 30% in the
placebo group, a study population of 100 patients was
expected to have 80% power to detect a 20% reduction in IR.
For primary endpoint outcomes, all differences in preoperative
variables with a P value of less than 0.15 in the univariate anal-
ysis of the controlled study were entered into a logistic regres-
sion analysis. Results for qualitative variables are expressed as
frequency and percentage. Quantitative variables are
expressed as mean ± standard deviation or as median and
interquartile range in the case control study and as mean and
95% CI in the controlled study. A P value of less than 0.05
was considered statistically significant. For primary endpoint
outcomes of the controlled study, exact P values are reported.
SPSS version 12.2 (SPSS Inc., Chicago, IL, USA) was used.
Results
Part 1: Assessment of postoperative incidence and 
protective/risk factors for inflammatory response after 
cardiopulmonary bypass
Of 165 patients, 34 (20.6%) fulfilled the criteria for IR. At 4
hours after intervention, patients who developed IR presented
higher cardiac rates (107 ± 17 beats per minute [versus 87 ±
12 bpm; P < 0.001) and lower systolic arterial pressures (107
± 20 mm Hg versus 136 ± 15.4 mm Hg; P < 0.001). These
patients presented significantly higher levels of IL-6 at 4 hours:
418 ± 216 pg/mL versus 232 ± 198 pg/mL in the non-IR
group (P = 0.033) (Figure 1). Also, IR patients showed signif-
icantly higher 24-hour postoperative bleeding of 835 (670 to
950) mL as compared to non-IR patients with 585 (425 to
746) mL (P = 0.002) with no significant differences in transfu-
sion requirements between groups (Figure 2).
Table 1 shows demographic and clinical data of patients who
developed IR as compared with those without IR. The only sig-
nificant difference in the univariate analysis was the use of TA,
which was associated with a lower incidence of IR (P  =Critical Care    Vol 11 No 6    Jimenez et al.
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0.002). IR was found in 26 (33%) of 79 patients who did not
receive TA versus 8 (9%) of 86 patients who received TA. Ini-
tially, we included aortic clamping time (P = 0.11), mixed car-
diac surgery (P = 0.05), and TA administration (P < 0.01).
Only the use of TA proved to be an independent protective
variable (odds ratio [OR] 0.38, 95% confidence interval [CI]
0.18 to 0.81; P = 0.009).
Twenty (12%) of the 165 patients presented VS. In the non-
TA group, 16 (20%) out of 79 patients developed VS. As
expected, patients with IR were more likely to develop VS
(58% versus 0%; P < 0.001). There were 3 deaths (1.8%) in
the whole group; none of them had developed IR.
Part 2: Prospective double-blind trial of tranexamic acid 
effect on inflammatory response after cardiopulmonary 
bypass
The study was interrupted by the ethics committee after the
inclusion of 50 patients due to the higher proportion of severe
bleeding observed in the placebo group during follow-up. The
primary analysis was intention-to-treat and involved all patients
who were randomly assigned. We studied 50 patients, 24
receiving TA and 26 placebo, from 68 consecutive patients, of
whom 18 met criteria for exclusion (5 off-pump, 2 with previ-
ous surgery coagulation disorders, 5 surgical emergencies, 1
Jehovah's Witness, 4 with endocarditis, and 1 with chronic
renal failure on hemodialisis) (Figure 3). Demographic varia-
bles, comorbidity, medical treatment, preoperative biochemi-
cal data, and surgical procedures were similar in the two
groups (Table 2).
The incidence of IR was significantly lower in the TA group
(17%) than in the placebo group (42%) (P  = 0.047). TA
showed a protective effect for IR (OR 0.1, 95% CI 0.01 to 0.7)
after adjusting for Parsonnet score, aortic clamping time, and
type of surgery. As compared with the TA group, the relative
risk for developing IR was 2.47 for the placebo group (97.5%
CI 1.1 to 5.7). The absolute risk difference was 25%. Thus, the
number needed to treat to reduce IR was 4 patients (97.5%
CI 2 to 20 patients). The incidence of VS was 0% in the TA
group versus 23% in the placebo group (P < 0.001).
The TA group had significantly lower 24-hour chest tube
bleeding (P < 0.001) (Figure 4) and transfusion requirements
before ICU discharge compared with the placebo group. In
addition, the TA group required significantly less vasopressor
medication and mechanical ventilation time. We did not find
significant differences in duration of ICU stay or hospital stay
after surgery between groups (Table 3). One patient from the
placebo group required reintervention due to nonsurgical
bleeding. There were no deaths in this study.
Table 3 shows the biological variables studied in both groups.
Significantly lower D-dimer (Figure 5), PAI-1, and creatine-
kinase levels were observed in patients in the TA group within
the first 24 hours after CPB; lower levels of STNFR and IL-6
were observed in the TA group, but these differences were not
significant. The remaining variables (coagulation parameters)
did not show significant differences (data not shown).
Discussion
Part 1: Assessment of postoperative incidence and 
protective/risk factor for inflammatory response after 
cardiopulmonary bypass
According to previous reports, it is widely accepted that a sys-
temic response is induced in nearly all patients undergoing
open-heart surgery [1]. The occurrence rate of a hyperdy-
namic state after CPB has been reported to be as low as 4%.
[7] and as high as 44% [8]. Indeed, much of the difference in
prevalence may relate to the criteria used to define the
vasodilatory syndrome [9]. The American College of Chest
Figure 1
Levels of interleukin-6 (IL-6) at 4 hours between inflammatory response  (IR) patients and non-IR patients Levels of interleukin-6 (IL-6) at 4 hours between inflammatory response 
(IR) patients and non-IR patients. ICU, intensive care unit.
Figure 2
Relationship between 24-hour chest tube bleeding and inflammatory  response Relationship between 24-hour chest tube bleeding and inflammatory 
response. Horizontal lines represent the median, boxes encompass the 
25th to 75th percentile, and error bars encompass the 10th to 90th 
percentile.Available online http://ccforum.com/content/11/6/R117
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Physicians/Society of Critical Care Medicine consensus pro-
posed a very sensitive, but very low-specificity, definition for
systemic IR syndrome [10]. This definition is often inappropri-
ate for cardiac surgery patients (mechanically ventilated, hypo-
thermic, with pacemakers, and so on), and therefore we
applied a definition based on hemodynamic data provided by
the latest International Definitions Conference [11]. Other
studies have proposed definitions based on analytical data
such as high levels of IL-6 [12], whose serum concentrations
correlate with morbidity and mortality following pediatric car-
diac surgery [13]. The present study has shown that patients
who fulfilled clinical criteria also had higher levels of IL-6.
Therefore, the definition used seemed to be suitable to identify
protective or risk factors for IR after CPB, even though this
clinical picture may vary from mild to severe form. IR was found
in one fourth of the patients, of whom more than half devel-
oped VS. TA was significantly associated with a lower inci-
dence of IR. The incidence in those patients who did not
receive TA was nearly one third, similar to other reports [12].
Thus, the next step was to test this hypothesis using an exper-
imental design.
Part 2: Prospective double-blind trial of tranexamic acid 
effect on inflammatory response after cardiopulmonary 
bypass
The trial was interrupted by the ethics committee due to the
adverse effects (excessive bleeding) observed in the placebo
group during follow-up. Our results indicate that TA reduces
the incidence of IR and VS in CPB patients as well as postop-
erative bleeding and hemoderivative requirements. Several
mechanisms have been proposed to explain the development
of IR after CPB, such as contact activation, ischemia-reper-
fusion, and endotoxemia. These initiating factors may activate
numerous systems involving complement, cytokines, immune
cellular response with dysfunction of endothelium, and altera-
tion of coagulation-fibrinolytic cascades [1]. This activation
exposes patients to either immediate risk of major bleeding
[14] or IR, as we saw in the first part of the study. The IR in car-
Table 1
Part 1. Patient characteristics and associations with inflammatory response after cardiopulmonary bypass
Variables Inflammatory response (n = 34) No inflammatory response (n = 131) P value
Age, years 61 ± 12 61 ± 13 0.97
Gender
Male, number (percentage) 24 (70) 88 (67) 0.70
Female, number (percentage) 10 (30) 43 (33) 0.70
Body mass index, kg/m2 28.5 ± 5 27.5 ± 4.2 0.20
Parsonnet score 13.6 ± 9.2 12.1 ± 6.8 0.35
Comorbidity
Renal disease, number (percentage) 4 (11) 8 (6) 0.26
Diabetic status, number (percentage) 12 (35) 44 (34) 0.85
Angiotensin-converting enzyme inhibitors, number 
(percentage)
10 (29) 45 (34) 0.58
Cardiac intervention
Coronary, number (percentage) 19 (56) 81 (62) 0.20
Valvular, number (percentage) 9 (26) 41 (31) 0.58
Both, number (percentage) 6 (17) 9 (7) 0.051
Reintervention, number (percentage) 2 (6) 6 (5) 0.75
Surgical data
Total cardiopulmonary bypass time, minutes 101 ± 33 93 ± 33 0.20
Aortic clamping time, minutes 61.6 ± 27.3 54 ± 22.8 0.11
Tranexamic acid, number (percentage) 8 (26) 78 (60) <0.01
No antifibrinolytics, number (percentage) 26 (76) 53 (40) 0.44
Intensive care unit stay, days 7.8 ± 6.4 3.2 ± 1.7 <0.01
Hospital stay, days 17.6 ± 20.5 9.1 ± 6.2 <0.01
Values are expressed as mean ± standard deviation.Critical Care    Vol 11 No 6    Jimenez et al.
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diac surgery is closely related to hemostatic alterations. [15].
In this sense, higher D-dimer and IL-6 levels have been found
in CPB patients with vasoplegic syndrome. [16]. In fact, IR and
major bleeding could be considered as final outcomes of the
same triggering stimulus, so that hyperfibrinolysis could play
an important role in these processes. [17,18]. The suppres-
sion of excessive plasmin activity or D-dimer formation may
play an important role in the generation of proinflammatory
cytokine (IL-6) during and after CPB [5], which has been
reported to be involved in circulatory dysregulation and meta-
bolic derangement [4].
TA, an antifibrinolytic agent. [19], reduces bleeding and trans-
fusion requirements after cardiac surgery. [20,21]. A synthetic
derivative of the amino acid lysine, TA exerts its antifibrinolytic
effect through the reversible blockade of lysine-binding sites
on plasminogen molecules. However, the effect of TA on IR
during cardiac surgery and CPB has received little attention
[22]. In our study, low levels of D-dimer at all postoperative
time points in the TA group clearly suggest that these patients
experienced less secondary fibrinolysis which leads to
reduced postoperative bleeding. Lower levels of PAI-1 at 4
hours may reflect less previous activation of fibrinolysis with
less secondary production. We observed no striking changes
in coagulation and complement parameters in the TA group.
However, STNFR levels and IL-6 levels at 4 hours, which have
been implicated in the development of postoperative morbidity
after CPB [23], were lower, as were myocardial enzymes on
admission, which may reflect a reduced IR [24] and thus less
perioperative insult. Casati and colleagues [25] have proven
that TA can effectively decrease postoperative IL-6 levels in
this context. Blood transfusions are able to alter the IR,
including cytokine concentrations of IL-6. However, we sup-
pose that an influence of transfusions on the postoperative
development of IR can be ruled out by the fact that only three
patients were transfused before setting up the clinical criteria
for IR. Furthermore, the number of red blood cell units given
during the first hours of the postoperative period did not differ
Figure 3
Randomized control trial flow diagram Randomized control trial flow diagram.
POTENTIAL ELIGIBLE PATIENTS
n=70 
NON SELECTED (n=18)
-OFF PUMP (n=5)
-PREVIOUS COAGULATION DISORDER (n=2)
-SURGICAL EMERGENCIES (n=5)
-JEHOVA S WITNESS (n=1)
-ENDOCARDITIS (n=4)
-HEMODIALYSIS (n=1
SELECTED 
n=50 
TRANEXAMIC ACID
n=24
IR
n=4
NO  IR
n=20
PLACEBO
n=26
IR
n=11
VS
n=7 
NO VS 
n=4
NO IR
n=15 
IR: Inflammatory Response
VS: Vasoplegic ShockAvailable online http://ccforum.com/content/11/6/R117
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significantly between groups. Finally, due to the fact that
vasodilator drugs may interact with vascular resistance, the
inclusion of temperature as part of the clinical criteria rules out
the confounding effect of these drugs.
The TA patients needed smaller amounts of vasopressors and
shorter duration of mechanical ventilation. Greater bleeding
may lead to higher doses of vasopressor but not simply
because of a direct mechanistic principle. Other factors are
implicated; there is evidence that several shared key compo-
nents of IR are activated in major bleeding [26] and in vasople-
gia after CPB. [16]. Therefore, we may consider that the use
of a vasopressor does not depend exclusively on the amount
of bleeding. We believe that TA could attenuate inflammatory
changes through blockade of fibrinolysis and may modulate
interactions between the different systems involved in the glo-
bal response to CPB [1].
Table 2
Part 2. Baseline clinical data of controlled study (n = 50)
Variables Tranexamic acid (n = 24) Placebo (n = 26) P value
Demographic
Age, years 66 (63–70) 67 (62–71) 0.91
Male gender, number (percentage) 12 (50) 15 (57) 0.58
Body mass index, kg/m2 28 (25.8–30.1) 28.1 (36.4–29.7) 0.98
Parsonnet score 13.1 (11.8–15.5) 17.5 (13.7–21.3) 0.07
Comorbidity
Cardiopathy, number (percentage)
Coronary 13 (54) 12 (46) 0.71
Valve 9 (38) 10 (39) 0.68
Mixed 2 (8) 4 (15) 0.44
Medical treatment
Angiotensin-converting enzyme inhibitors, number (percentage) 11 (61) 7 (39) 0.16
Calcium channel blockers, number (percentage) 6 (60) 4 (40) 0.39
Preoperative parameters
Platelet count, × 103/mL 210 (186–234) 210 (186–239) 0.68
Hemoglobin, g/dL 14.1 (13.5–14.6) 13.6 (12.8–14.4) 0.42
International normalized ratio 1.08 (1.05–1.12) 1.09 (1.05–1.14) 0.97
D-dimer, ng/mL 250 (166–333) 275 (215–325) 0.34
Plasminogen activator inhibitor 1, ng/mL 34.2 (29–39.5) 35.2 (29.4–41.1) 0.95
Surgical data
Cardiopulmonary bypass time, minutes 82 (71–94) 85 (74–96) 0.30
Aortic clamping time, minutes 51 (44–58) 55 (47–62) 0.35
Temperature after cardiopulmonary bypass, degrees Celsius 35.3 (34.9–35.6) 35.1 (34.7–35.3) 0.24
Total heparin dose, UI/kg 430 (400–470) 420 (400–440) 0.69
Total protamine dose, mg/kg 2.7 (2.5–3) 2.7 (2.6–2.9) 0.72
Blood salvage device, mL 681 (605–756) 764 (694–833) 0.12
Values are expressed as mean and 95% confidence interval or as frequency and percentage.Critical Care    Vol 11 No 6    Jimenez et al.
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Limitations of the study
Even though greater postoperative bleeding was associated
with IR after CPB, a limitation was the failure to determine
fibrinolysis parameters in the first part of the study. The main
limitation of part 2 of the study is the sample size. However,
this was a randomized controlled study and baseline data
were comparable between groups. Additionally, although
inclusion of patients was prematurely stopped, data analysis
demonstrated that TA attenuates IR in patients after CPB.
This small sample size could lead to a type II error regarding
secondary endpoints, such as durations of hospital stay and
ICU stay.
Conclusion
The use of TA attenuates the development of IR and VS after
CPB, with hyperfibrinolysis playing a predominant role in
their development.
Figure 4
Twenty-four-hour chest tube bleeding between tranexamic acid and  placebo groups Twenty-four-hour chest tube bleeding between tranexamic acid and 
placebo groups. Horizontal lines represent the median, boxes encom-
pass the 25th to 75th percentile, and error bars encompass the 10th to 
90th percentile.
Table 3
Part 2. Clinical outcomes of the controlled study
Variables Tranexamic acid (n = 24) Placebo (n = 26) P value
D-dimer at 0 hours, ng/mLa 448 (270–625) 1,069 (951–1,189) <0.01
D-dimer at 4 hours, ng/mL 499 (364–633) 974 (880–1,069) <0.01
D-dimer at 24 hours, ng/mL 433 (280–608) 976 (868–1,064) <0.01
Plasminogen activator inhibitor 1 at 4 hours, ng/mL 88 (35–140) 129 (70–188) 0.04
Creatine-kinase at 0 hours, U/L 261 (199–322) 327 (270–383) 0.03
Creatine-kinase MB at 0 hours, U/L 41 (35–47) 63 (50–77) <0.01
STNFR-1 at 4 hours, ng/mL 1,274 (958–1,590) 1,656 (1,175–2,138) 0.09
Interleukin-6 at 4 hours, pg/mL 236 (140–332) 362 (250–474) 0.12
Interleukin-6 at 24 hours, pg/mL 87 (61–114) 119 (88–151) 0.07
Twenty-four-hour bleeding, mL 464 (308–620) 1,037 (771–1,303) <0.01
Total bleeding, mL 835 (407–1,263) 1,466 (1,116–1,818) <0.01
RBCb units transfused within the first 4 hours (percentage)c 1 (4) 2 (7) 0.39
RBCb units until chest tube withdrawal (percentage)c 9 (38) 19 (73) 0.01
Plasma units until chest tube withdrawal (percentage)c 1 (4) 8 (31) 0.02
Inflammatory response after CPB, number (percentage) 4 (17) 11 (42) 0.047
Vasoplegic shock, number (percentage) 0 7 (27) <0.01
Norepinephrine, hours 1.2 (0.5–2.4) 25.4 (5.6–45) 0.02
Mechanical ventilation, hoursd 6.5 (5–13.5) 12 (7–24) 0.02
Intensive care unit stay, daysd 3 (2–5.5) 3.5 (2–5) 0.96
Postsurgical hospital stay, daysd 4.5 (3–6) 4 (2–5) 0.34
Values are expressed as mean and 95% confidence interval or as frequency and percentage. a0 hours represents intensive care unit admission 
after cardiopulmonary bypass (CPB); btotal red blood cell (RBC) and plasma until chest tube withdrawal; cpercentage of transfused patients; 
dvalues are expressed as median and interquartile range. STNFR-1, soluble tumor necrosis factor receptor type 1.Available online http://ccforum.com/content/11/6/R117
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